As volatility returns to European markets, investors are turning to dividend-paying stocks for income and stability. We examine three companies with compelling, yet distinct, dividend profiles for income-focused portfolios.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
A notable investment fund has significantly reduced its position in Sirius XM Holdings, reflecting growing concerns over the audio giant's growth trajectory and competitive challenges, even as the company maintains strong cash generation.
The Supreme Court of British Columbia has granted final approval for Coeur Mining's acquisition of New Gold, moving the deal into its final regulatory phase. The transaction, poised to significantly expand Coeur's precious metals footprint, advances as the miner's stock shows considerable strength over the past year.
After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.
Bishkek moves to engage Brussels after reports emerge that the EU is preparing to deploy its new anti-circumvention tool, targeting Kyrgyzstan's role as a conduit for goods to sanctioned Russia.
With the 2025 tax filing season now open, millions of Americans are looking ahead to their 2026 refunds. We break down how to track your payment, expected wait times, and the potential impact of recent legislation on your bottom line.
A damning report from the European Court of Auditors reveals the bloc is falling dangerously behind in securing the lithium, cobalt, and nickel needed for its energy transition, leaving climate goals and strategic autonomy in jeopardy.
Tesla's sales decline in Europe continues despite new lower-cost models, while industry buzz swirls around a hotly denied report of potential Ford-Xiaomi collaboration. Meanwhile, U.S. dealers show surprising pragmatism toward the EV transition.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
The investment giant Vanguard has cut management fees on 53 of its mutual funds and ETFs, a move projected to save investors nearly $250 million in 2026 and marking the latest salvo in an industry-wide race to lower costs for everyday savers.
First Pacific Advisors' FPA Crescent Fund disclosed it sold its position in tech giant Microsoft in Q4 2025. The value-focused fund explained the move was driven by a search for greater upside in other AI-related investments, despite acknowledging Microsoft's strong fundamentals.
The European Union has firmly rejected Iran's retaliatory designation of EU member states' armed forces as 'terrorist groups,' a move that came days after the bloc formally listed Iran's Islamic Revolutionary Guard Corps (IRGC) as a terrorist organization, escalating a diplomatic tit-for-tat.
The Qatar Investment Authority has backed a new $200 million fund by Shorooq Partners, aiming to inject institutional capital into the region's mature startups and bridge a critical funding hurdle on the path to public listings.
A landmark tripartite agreement between financial heavyweight Schroders, battery leader CATL, and investment firm Lochpine Capital aims to deploy up to 10GWh of energy storage across Europe, marking a significant step in the continent's clean energy transition.
Alphabet's self-driving unit Waymo is in advanced talks to secure a massive $16 billion funding round, potentially valuing the company at around $110 billion, as competition in the robotaxi market intensifies.
